Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
Affimed stock logo
AFMD
Affimed
$5.15
+3.0%
$5.54
$2.23
$11.10
$78.43M2.0596,346 shs4,831 shs
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$4.53
+2.7%
$5.81
$1.03
$9.39
$479.68M1.811.95 million shs123,141 shs
Cerecor Inc. stock logo
CERC
Cerecor
$12.21
+5.0%
$2.60
$1.98
$4.50
$1.17B1.441.27 million shs83,471 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.81
+2.1%
$18.88
$10.06
$21.72
$372.82M0.8250,491 shs4,405 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Affimed stock logo
AFMD
Affimed
-2.91%-8.93%+0.20%-14.09%-41.15%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
+0.68%-12.85%-34.67%+63.33%+366.17%
Cerecor Inc. stock logo
CERC
Cerecor
+4.99%-18.05%+150.20%+168.35%+320.31%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
+0.62%+4.69%-1.67%+10.47%+78.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
3.4742 of 5 stars
3.53.00.04.31.10.00.6
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
4.668 of 5 stars
4.53.00.04.71.33.30.6
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.6982 of 5 stars
2.55.00.00.00.51.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
3.00
Buy$45.00773.79% Upside
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
3.00
Buy$11.60156.07% Upside
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0021.15% Upside

Current Analyst Ratings

Latest APLT, AFMD, CERC, ADMS, and NATR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$12.00
4/1/2024
Affimed stock logo
AFMD
Affimed
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/1/2024
Affimed stock logo
AFMD
Affimed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$30.00 ➝ $25.00
4/1/2024
Affimed stock logo
AFMD
Affimed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00
3/26/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
3/15/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
3/6/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $12.00
2/22/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/22/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
2/16/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $7.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
Affimed stock logo
AFMD
Affimed
$8.95M8.76N/AN/A$4.19 per share1.23
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$9.99M48.02N/AN/A($0.20) per share-22.65
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M174.97N/AN/A$0.22 per share55.50
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.84$1.64 per share12.09$8.36 per share2.37

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
Affimed stock logo
AFMD
Affimed
-$114.66M-$8.40N/AN/AN/A-1,280.27%-118.17%-81.35%5/28/2024 (Estimated)
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.73N/A3.39%12.25%7.75%5/14/2024 (Estimated)

Latest APLT, AFMD, CERC, ADMS, and NATR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
3/6/2024Q4 2023
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$0.15-$0.33-$0.18-$0.33N/A($0.67) million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
N/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
Affimed stock logo
AFMD
Affimed
0.11
3.25
3.23
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/A
0.76
0.76
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
69.97%
Affimed stock logo
AFMD
Affimed
30.82%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
98.31%
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%

Insider Ownership

CompanyInsider Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
18.90%
Affimed stock logo
AFMD
Affimed
3.80%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
19.10%
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
Affimed stock logo
AFMD
Affimed
21915.23 million14.65 millionOptionable
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
25105.89 million85.66 millionOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.90 millionOptionable

APLT, AFMD, CERC, ADMS, and NATR Headlines

SourceHeadline
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM
Nature’s Sunshine Recognized with Best Company Culture AwardNature’s Sunshine Recognized with Best Company Culture Award
finance.yahoo.com - December 19 at 10:07 AM
Natures Sunshine Products Stock (NASDAQ:NATR), Quotes and News SummaryNatures Sunshine Products Stock (NASDAQ:NATR), Quotes and News Summary
benzinga.com - December 12 at 11:35 PM
Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93
msn.com - November 27 at 7:16 PM
The Return Trends At Natures Sunshine Products (NASDAQ:NATR) Look PromisingThe Return Trends At Nature's Sunshine Products (NASDAQ:NATR) Look Promising
finance.yahoo.com - November 23 at 6:51 PM
Investing in Natures Sunshine Products (NASDAQ:NATR) a year ago would have delivered you a 108% gainInvesting in Nature's Sunshine Products (NASDAQ:NATR) a year ago would have delivered you a 108% gain
finance.yahoo.com - November 9 at 3:15 PM
Natures Sunshine Products Inc NATRNatures Sunshine Products Inc NATR
morningstar.com - November 8 at 6:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamas Pharmaceuticals logo

Adamas Pharmaceuticals

NASDAQ:ADMS
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Affimed logo

Affimed

NASDAQ:AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Applied Therapeutics logo

Applied Therapeutics

NASDAQ:APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Cerecor logo

Cerecor

NASDAQ:CERC
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.